Viridian Therapeutics, Inc.
VRDN
$23.02
-$0.15-0.65%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 23,220.33% | 23,382.78% | 23,359.93% | 23,340.07% | 5.90% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 23,220.33% | 23,382.78% | 23,359.93% | 23,340.07% | 5.90% |
| Cost of Revenue | 7.75% | 25.20% | 43.72% | 57.03% | 83.39% |
| Gross Profit | 15.52% | 0.56% | -14.13% | -22.66% | -83.53% |
| SG&A Expenses | 125.30% | 85.07% | 56.04% | -1.61% | -20.81% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 29.02% | 36.41% | 46.24% | 40.79% | 48.12% |
| Operating Income | -9.99% | -15.49% | -22.69% | -15.93% | -48.17% |
| Income Before Tax | -12.47% | -16.95% | -26.91% | -17.46% | -50.87% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -12.47% | -16.95% | -26.91% | -17.46% | -50.87% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.47% | -16.95% | -26.91% | -17.46% | -50.87% |
| EBIT | -9.99% | -15.49% | -22.69% | -15.93% | -48.17% |
| EBITDA | -10.01% | -15.53% | -22.76% | -15.99% | -48.31% |
| EPS Basic | 5.67% | 0.39% | -7.62% | -29.53% | -40.24% |
| Normalized Basic EPS | 11.53% | 5.68% | -1.91% | 13.77% | -4.80% |
| EPS Diluted | 5.67% | 0.39% | -7.62% | -29.53% | -40.24% |
| Normalized Diluted EPS | 11.53% | 5.68% | -1.91% | 13.77% | -4.80% |
| Average Basic Shares Outstanding | 24.84% | 23.42% | 24.93% | 34.73% | 41.74% |
| Average Diluted Shares Outstanding | 24.84% | 23.42% | 24.93% | 34.73% | 41.74% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |